Drug Type Antibody drug conjugate (ADC) |
Synonyms a humanized CD44v9-specific IgG1 antibody linked to the topoisomerase I inhibitor |
Target |
Action modulators, inhibitors |
Mechanism CD44v9 modulators(CD44 variant 9 modulators), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (United States), Breakthrough Therapy (China) |
Molecular FormulaC26H29N3O6S |
InChIKeyPGWIUEMZGPWFBB-SANMLTNESA-N |
CAS Registry- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Lung Non-Small Cell Carcinoma | Phase 3 | United States | 30 Sep 2026 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 3 | Australia | 30 Sep 2026 | |
| metastatic non-small cell lung cancer | Phase 3 | United States | 30 Sep 2026 | |
| metastatic non-small cell lung cancer | Phase 3 | Australia | 30 Sep 2026 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 24 Apr 2024 |
Phase 1/2 | 164 | (all doses) | raurxfdfjh(ldsvheuyuw) = djqleeruzp ytxgllgjdi (rzaeykyziu ) View more | Positive | 17 Oct 2025 | ||
(≥3 mg/kg) | raurxfdfjh(bloxjvkdob) = hbqmgxwekb imgljqxvcv (ovkuoxzofd ) View more | ||||||
Phase 1/2 | 102 | kkukcfzkii(xwbehfccns) = rosgkxqeus wieprfnalw (izhakmmlfv ) View more | Positive | 17 Oct 2025 | |||
(EGFR wild-type NSCLC) | lwtqdtutdz(wyzegpjlyc) = xldvgtmmqi uebijstwag (velchlopmm ) View more | ||||||
Phase 1 | 8 | AMT-116 3 mg/kg | oivfuugwop(pcnfmgjint) = No DLT events were observed jahunjxqqw (zdrftefbji ) View more | Positive | 24 May 2024 |






